<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376102</url>
  </required_header>
  <id_info>
    <org_study_id>111412</org_study_id>
    <nct_id>NCT01376102</nct_id>
  </id_info>
  <brief_title>BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)</brief_title>
  <acronym>BONINJPMS</acronym>
  <official_title>An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Injection Administered in Korean Patients According to the Prescribing Information</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-centre, non-interventional post-marketing surveillance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-centre, non-interventional post-marketing surveillance to
      monitor the safety of Ibandronate injection administered in postmenopausal osteoporosis
      patients according to the prescribing information
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of adverse event after ibandronate administration</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of unexpected adverse drug reaction after BONVIVA(ibandronate) injection administration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of serious adverse event after BONVIVA(ibandronate) injection administration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of BONVIVA(ibandronate) injection treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">657</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>BONVIVA(ibandronate)</arm_group_label>
    <description>Patients administrated ibandronate injection with postmenopausal osteoporosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BONVIVA(ibandronate) injection</intervention_name>
    <description>Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.</description>
    <arm_group_label>BONVIVA(ibandronate)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients administrated BONVIVA(ibandronate) injection with postmenopausal osteoporosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy the following criteria at study entry:

        Subjects administered with BONVIVA(ibandronate) injection following the locally approved
        prescribing information Women diagnosed with postmenopausal osteoporosis. Subjects who the
        investigator believes that they can and will comply with the requirements of the protocol
        Subjects with no experience of treatment using ibandronate injection Note: Subjects, who
        have experience of other bisphosphonates treatment, can be included.

        Subjects who are indicated and administered of ibandronate injection according to the
        Prescribing Information in normal prescription use

        Exclusion Criteria:

        Considering the nature of this non-interventional PMS, there is no strict exclusion
        criteria set up. The doctors participating this study to enrol the subjects prescribed with
        ibandronate injection following the locally approved Prescribing Information.

        The following criteria should be checked at the time of study entry.

        According to contraindication on the prescribing information, ibandronate injection should
        not be administered to the following patients:

        Patients with known hypersensitivity to ibandronate injection or to any of its excipients
        Uncorrected hypocalcemia Note: Ibandronate injection is not recommended for use in patients
        who have a serum creatinine above 200 Î¼mol/l (2.3 mg/dl) or who have a creatinine clearance
        (measured or estimated) below 30 ml/min, because of limited clinical data available from
        studies including such patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>ibandronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

